USANA Health Sciences (USNA) Tops Q2 EPS by 19c

USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $0.89, $0.19 better than the analyst estimate of $0.70. Revenue for the quarter came in at $238 million versus the consensus estimate of $231.14 million.

GUIDANCE:

USANA Health Sciences sees FY2023 EPS of $2.65-$3.30, versus the consensus of $3.02. USANA Health Sciences sees FY2023 revenue of $900-950 million, versus the consensus of $940.57 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Tepper’s Appaloosa soars 32% in H1 on prescient memory-chip bets - report
• RxSight cuts 2026 sales outlook, citing competitive headwinds